Molecular Approach to Optimal Choice of Specific Immunotherapy for Patients with Sensitization to Weed Pollen Allergens

Svitlana Zubchenko
2017 Journal of Medical Science And clinical Research  
The problem of pollen allergy, particularly pollen of weeds is urgent for the population of Western Ukraine, including Lviv region. Aim: To compare possibility of SPT and component diagnostics for the selection of appropriate specific immunotherapy. Materials and Methods: Forty eight patients of both sexes, aged 23.0±2.7 years, residents of Lviv region with seasonal allergic rhinitis / conjunctivitis, were selected according to primary stay in the first week of August of the current year. SPT
more » ... current year. SPT to extracts of pollen allergens from local sources was performed, including a mixture of weeds, grasses and extracts of mugwort, ragweed, timothy ("Immunologist", Ukraine). Immuno CAP (Thermo Scientific, Uppsala, Sweden) was used for molecular investigations of sIgE. Results: Positive SPT to weed mixture, extracts of ambrosia, ragweed and grass mixtures was found in 50% of patients. This indicated co-sensitization to various sources of allergens; 29.2% of patients had monosensitization to weed pollen, and 20.8%monosensitization to grass pollen. However, simultaneous sensitization to pollen of mugwort, ragweed and timothy was not proven by molecular investigations. Instead, it was found that 20.8% of patients had sensitization to ragweed and mugwort, 29.2% of individuals monosensitization to ragweed, and 20.8%monosensitization to mugwort. Most (70.8%) patients with monosensitization to weed pollen had specific IgE to Art v1 and/or Art v3, and / or Amb a1. False positive Impact Factor 5.84 Index Copernicus Value: 71.58 JMSCR Vol||05||Issue||09||Page 28311-28315||September 2017 results of SPT indicated that co-sensitization to grasses and weeds can be explained by the presence of sIgE for cross-reactive markers of profilin Phl p 12 and polcalcin -Phl p 7. Conclusion: Based on SPT and molecular investigations the doctor makes a fundamentally different decision on the selection of extracts for specific allergen immunotherapy. Optimal allergic immunotherapy is based on identification of primary sensitizer and cross-reactivity markers.
doi:10.18535/jmscr/v5i9.157 fatcat:32hi2d3l4rdnvjrg76o4ufvwfe